Skip to main content

No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 22, 2025.

By Lori Solomon HealthDay Reporter

WEDNESDAY, Jan. 22, 2025 -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online Jan. 16 in Thyroid.

Sarah M. Baxter, from Queen’s University Belfast in Northern Ireland, and colleagues investigated if GLP-1 RA use compared to use of dipeptidyl peptidase-4 inhibitors (DPP-4is) was associated with thyroid cancer risk in patients with type 2 diabetes. The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3.0 years.

The researchers found that GLP-1 RA use was not associated with an increased risk for thyroid cancer (pooled weighted hazard ratio, 0.81; 95 percent confidence interval, 0.59 to 1.12) compared with use of DPP-4i. Among GLP-1 RA ever-users, there was no increased risk in thyroid cancer with an increasing cumulative dose of GLP-1 RA.

"In this large multisite study, utilizing data from six population-based databases, we found no evidence that GLP-1 RA use is associated with an increased risk of thyroid cancer with follow-up ranging from 1.8 to 3.0 years, providing some reassurance to patients and clinicians about the short-term safety of these drugs," the authors write. "Nevertheless, evidence was insufficient to rule out excess risk with long-term use, due to the short follow-up."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

In Pediatric Leukemia, Survival Linked to Duration of Overweight, Obesity

TUESDAY, May 20, 2025 -- For children with acute lymphoblastic leukemia (ALL), longer duration of overweight or obesity is associated with lower overall and event-free survival...

GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression

MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...

Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery

THURSDAY, May 15, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.